271 related articles for article (PubMed ID: 16887291)
1. Using decision analysis to determine the cost-effectiveness of intensity-modulated radiation therapy in the treatment of intermediate risk prostate cancer.
Konski A; Watkins-Bruner D; Feigenberg S; Hanlon A; Kulkarni S; Beck JR; Horwitz EM; Pollack A
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):408-15. PubMed ID: 16887291
[TBL] [Abstract][Full Text] [Related]
2. Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10).
Konski A; Sherman E; Krahn M; Bremner K; Beck JR; Watkins-Bruner D; Pilepich M
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):788-94. PubMed ID: 16109464
[TBL] [Abstract][Full Text] [Related]
3. Long-term hormone therapy and radiation is cost-effective for patients with locally advanced prostate carcinoma.
Konski A; Watkins-Bruner D; Brereton H; Feigenberg S; Hanks G
Cancer; 2006 Jan; 106(1):51-7. PubMed ID: 16323171
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for anal cancer.
Hodges JC; Beg MS; Das P; Meyer J
Int J Radiat Oncol Biol Phys; 2014 Jul; 89(4):773-83. PubMed ID: 24726392
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of intensity-modulated radiotherapy in prostate cancer.
Yong JH; Beca J; McGowan T; Bremner KE; Warde P; Hoch JS
Clin Oncol (R Coll Radiol); 2012 Sep; 24(7):521-31. PubMed ID: 22705100
[TBL] [Abstract][Full Text] [Related]
6. Use of benchmark dose-volume histograms for selection of the optimal technique between three-dimensional conformal radiation therapy and intensity-modulated radiation therapy in prostate cancer.
Luo C; Yang CC; Narayan S; Stern RL; Perks J; Goldberg Z; Ryu J; Purdy JA; Vijayakumar S
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1253-62. PubMed ID: 17145540
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of intensity-modulated radiotherapy in oropharyngeal cancer.
Yong JH; Beca J; O'Sullivan B; Huang SH; McGowan T; Warde P; Hoch JS
Clin Oncol (R Coll Radiol); 2012 Sep; 24(7):532-8. PubMed ID: 22739256
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and cost-effectiveness analysis of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for postoperative treatment of gynecologic cancers.
Chen LA; Kim J; Boucher K; Terakedis B; Williams B; Nickman NA; Gaffney DK
Gynecol Oncol; 2015 Mar; 136(3):521-8. PubMed ID: 25562668
[TBL] [Abstract][Full Text] [Related]
9. A decision model to estimate the cost-effectiveness of intensity modulated radiation therapy (IMRT) compared to three dimensional conformal radiation therapy (3DCRT) in patients receiving radiotherapy to the prostate bed.
Carter HE; Martin A; Schofield D; Duchesne G; Haworth A; Hornby C; Sidhom M; Jackson M
Radiother Oncol; 2014 Aug; 112(2):187-93. PubMed ID: 24929702
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of intensity-modulated radiation therapy.
Konski A
Expert Rev Pharmacoecon Outcomes Res; 2005 Apr; 5(2):137-40. PubMed ID: 19807569
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
[TBL] [Abstract][Full Text] [Related]
12. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer.
Vora SA; Wong WW; Schild SE; Ezzell GA; Halyard MY
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(4):1053-8. PubMed ID: 17398023
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of SBRT versus IMRT for low-risk prostate cancer.
Sher DJ; Parikh RB; Mays-Jackson S; Punglia RS
Am J Clin Oncol; 2014 Jun; 37(3):215-21. PubMed ID: 23275277
[TBL] [Abstract][Full Text] [Related]
14. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?
Konski A; Speier W; Hanlon A; Beck JR; Pollack A
J Clin Oncol; 2007 Aug; 25(24):3603-8. PubMed ID: 17704408
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness studies in radiation therapy.
Sher DJ
Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):567-82. PubMed ID: 20950072
[TBL] [Abstract][Full Text] [Related]
16. Upfront treatment of locally advanced cervical cancer with intensity modulated radiation therapy compared to four-field radiation therapy: a cost-effectiveness analysis.
Lesnock JL; Farris C; Beriwal S; Krivak TC
Gynecol Oncol; 2013 Jun; 129(3):574-9. PubMed ID: 23500086
[TBL] [Abstract][Full Text] [Related]
17. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
18. Intensity-modulated radiation therapy (IMRT) versus 3-dimensional conformal radiation therapy (3D-CRT) for head and neck cancer: cost-effectiveness analysis.
Marta GN; Weltman E; Ferrigno R
Rev Assoc Med Bras (1992); 2018 Apr; 64(4):318-323. PubMed ID: 30133610
[TBL] [Abstract][Full Text] [Related]
19. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
20. Protons in head-and-neck cancer: bridging the gap of evidence.
Ramaekers BL; Grutters JP; Pijls-Johannesma M; Lambin P; Joore MA; Langendijk JA
Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1282-8. PubMed ID: 23273998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
